<DOC>
	<DOCNO>NCT00322374</DOCNO>
	<brief_summary>Tumor response information obtain participant receive least 2 cycle study drug , underwent requisite baseline on-treatment disease assessment least one post-treatment assessment . Tumor response assessment evaluable participant do accord Response Evaluation Criteria Solid Tumors ( RECIST ) criterion .</brief_summary>
	<brief_title>Phase I Combination w/ Epirubicin</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Women ≥18 year Histologically cytologically confirm diagnosis metastatic breast cancer Measurable nonmeasurable disease define Response Evaluation Criteria In Solid Tumors ( RECIST ) Number prior chemotherapy line treatment metastatic setting ≥2</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>